Evotec AG has entered a research collaboration and licensing agreement with Debiopharm Group to identify and develop compounds for the potential treatment of multiple forms of solid tumors and leukemias, with defined genetic alterations.   Evotec will provide discovery and preclinical development services and Debiopharm will be responsible for clinical development. Evotec will receive R&D funding and payments based on clinical, regulatory and commercial milestones, as well as royalties on sa...